Default: Endocrine Practice

ISSN: 1530-891X

Journal Home

Journal Guideline

Endocrine Practice Q2 Unclaimed

American Association of Clinical Endocrinology United States
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Endocrine Practice is a journal indexed in SJR in Medicine (miscellaneous) and Endocrinology with an H index of 87. It has an SJR impact factor of 0,93 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,93.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Metrics

Endocrine Practice

0,93

SJR Impact factor

87

H Index

205

Total Docs (Last Year)

582

Total Docs (3 years)

4874

Total Refs

1319

Total Cites (3 years)

426

Citable Docs (3 years)

1,86

Cites/Doc (2 years)

23,78

Ref/Doc



Best articles by citations

Subtotal Parathyroidectomy for Primary Hyperparathyroidism

View more

Reliability of Early Iodine 123 Uptake for Treatment of Graves Disease in Children

View more

Biochemical Diagnosis of Adrenal Insufficiency: The Added Value of Dehydroepiandrosterone Sulfate Measurements

View more

IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE

View more

EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM

View more

ENERGY EXPENDITURE IN 21-HYDROXYLASE CONGENITAL ADRENAL HYPERPLASIA PATIENTS AND COMPARISON WITH PREDICTIVE EQUATIONS

View more

Successful Treatment of Persistent Hyperinsulinemic Hypoglycemia with Nifedipine in an Adult Patient

View more

PROGNOSTIC IMPACT OF DIABETES MELLITUS ON OVERALL SURVIVAL IN A NATIONWIDE POPULATION-BASED COHORT OF PATIENTS WITH PANCREATIC CANCER

View more

RISK FACTORS FOR HYPOGLYCEMIA IN INPATIENTS WITH TOTAL PARENTERAL NUTRITION AND TYPE 2 DIABETES: A POST-HOC ANALYSIS OF THE INSUPAR STUDY

View more

EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

View more

Medical Management of Extrathyroidal Manifestation of Graves Disease

View more

THERAPEUTIC EFFECTS OF COMBINATION REGIMENS INCLUDING METHIMAZOLE ON GRAVES' HYPERTHYROIDISM: A NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

View more
SHOW MORE ARTICLES

TRENDS IN THE CARE AND OUTCOMES OF MEDICARE BENEFICIARIES WITH TYPE 2 DIABETES, 2002-2011

View more

Benign Familial Hypocalciuric Hypercalcemia

View more

RELATIONSHIP BETWEEN THE ENVIRONMENTAL ENDOCRINE DISRUPTOR BISPHENOL A AND DYSLIPIDEMIA: A FIVE-YEAR PROSPECTIVE STUDY

View more

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: POSTOPERATIVE HYPOPARATHYROIDISM - DEFINITIONS AND MANAGEMENT

View more

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: POSTOPERATIVE MANAGEMENT FOLLOWING PITUITARY SURGERY

View more

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE QUALITY OF DXA SCANS AND REPORTS

View more

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE EVALUATION AND TREATMENT OF HYPERTHYROIDISM AND HYPOTHYROIDISM

View more

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Management of Diabetes Mellitus

View more

American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement

View more

THYROID PEROXIDASE ANTIBODIES IN MEXICAN-BORN HEALTHY PREGNANT WOMEN, IN WOMEN WITH TYPE 2 OR GESTATIONAL DIABETES MELLITUS, AND IN THEIR OFFSPRING

View more

OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS

View more

SUPER BONE SCAN IN OSTEOPETROSIS

View more

Comments

No comments ... Be the first to comment!

FAQS